Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8.25
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8 to $8.25.
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8 to $8.25.